CN107427463A - 左旋多巴和卡比多巴肠凝胶以及使用方法 - Google Patents

左旋多巴和卡比多巴肠凝胶以及使用方法 Download PDF

Info

Publication number
CN107427463A
CN107427463A CN201680016049.3A CN201680016049A CN107427463A CN 107427463 A CN107427463 A CN 107427463A CN 201680016049 A CN201680016049 A CN 201680016049A CN 107427463 A CN107427463 A CN 107427463A
Authority
CN
China
Prior art keywords
pharmaceutical composition
levodopa
carbidopa
activating agent
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680016049.3A
Other languages
English (en)
Chinese (zh)
Inventor
R.孔吉瓦拉姆
A.迪奇
黄冶
S.E.麦基
R.A.门格斯
J.B.齐默曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Priority to CN202310053820.6A priority Critical patent/CN116036064A/zh
Publication of CN107427463A publication Critical patent/CN107427463A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
CN201680016049.3A 2015-01-20 2016-01-20 左旋多巴和卡比多巴肠凝胶以及使用方法 Pending CN107427463A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310053820.6A CN116036064A (zh) 2015-01-20 2016-01-20 左旋多巴和卡比多巴肠凝胶以及使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562105565P 2015-01-20 2015-01-20
US62/105,565 2015-01-20
US201562272922P 2015-12-30 2015-12-30
US62/272,922 2015-12-30
PCT/US2016/014005 WO2016118556A1 (en) 2015-01-20 2016-01-20 Levodopa and carbidopa intestinal gel and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310053820.6A Division CN116036064A (zh) 2015-01-20 2016-01-20 左旋多巴和卡比多巴肠凝胶以及使用方法

Publications (1)

Publication Number Publication Date
CN107427463A true CN107427463A (zh) 2017-12-01

Family

ID=55410198

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680016049.3A Pending CN107427463A (zh) 2015-01-20 2016-01-20 左旋多巴和卡比多巴肠凝胶以及使用方法
CN202310053820.6A Pending CN116036064A (zh) 2015-01-20 2016-01-20 左旋多巴和卡比多巴肠凝胶以及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310053820.6A Pending CN116036064A (zh) 2015-01-20 2016-01-20 左旋多巴和卡比多巴肠凝胶以及使用方法

Country Status (16)

Country Link
US (3) US10117843B2 (https=)
EP (2) EP3247330A1 (https=)
JP (4) JP2018503686A (https=)
KR (1) KR20170103967A (https=)
CN (2) CN107427463A (https=)
AU (1) AU2016209420B2 (https=)
BR (1) BR112017015613B1 (https=)
CA (1) CA2974203A1 (https=)
IL (1) IL253487A0 (https=)
MA (1) MA41377A (https=)
MX (1) MX384262B (https=)
PH (1) PH12017501304A1 (https=)
RU (1) RU2017129375A (https=)
SG (1) SG11201705964YA (https=)
TW (1) TW201639556A (https=)
WO (1) WO2016118556A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021103000A (ru) 2014-10-21 2021-03-01 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
JP2019523249A (ja) * 2016-07-20 2019-08-22 アッヴィ・インコーポレイテッド レボドパ及びカルビドパ腸管ゲル、並びに使用方法
BR112021009353A2 (pt) 2018-11-15 2021-11-23 Abbvie Inc Formulações farmacêuticas para administração subcutânea
CN119510592A (zh) * 2023-08-22 2025-02-25 上海汉都医药科技有限公司 一种含有卡比多巴的药物中肼含量的检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012153A1 (en) * 1992-11-30 1994-06-09 Nystroem Christer A pharmaceutical formulation
CN101636145A (zh) * 2006-05-31 2010-01-27 索尔瓦药物有限公司 长期24小时经肠给予左旋多巴/卡比多巴

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
ES2070994T3 (es) 1989-04-20 1995-06-16 Zambon Spa Profarmaco de dopamina.
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
PL2432454T3 (pl) 2009-05-19 2017-10-31 Neuroderm Ltd Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
PT2640358T (pt) * 2010-11-15 2018-02-23 Neuroderm Ltd Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos
WO2012079072A2 (en) 2010-12-10 2012-06-14 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US8765189B2 (en) 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
WO2013033453A2 (en) * 2011-08-31 2013-03-07 Abbott Laboratories Sealing arrangement for syringe
AU2014229127B2 (en) 2013-03-13 2018-04-05 Neuroderm Ltd Method for treatment of parkinson's disease
CN113384373B (zh) 2013-11-05 2022-10-21 辛纳吉勒公司 经由口腔进行连续药物递送的装置和方法
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012153A1 (en) * 1992-11-30 1994-06-09 Nystroem Christer A pharmaceutical formulation
CN101636145A (zh) * 2006-05-31 2010-01-27 索尔瓦药物有限公司 长期24小时经肠给予左旋多巴/卡比多巴

Also Published As

Publication number Publication date
MA41377A (fr) 2017-11-28
AU2016209420A1 (en) 2017-08-03
IL253487A0 (en) 2017-09-28
AU2016209420B2 (en) 2021-05-20
EP4470611A3 (en) 2025-02-19
MX384262B (es) 2025-03-14
BR112017015613B1 (pt) 2023-11-28
JP2023058678A (ja) 2023-04-25
WO2016118556A1 (en) 2016-07-28
RU2017129375A (ru) 2019-02-21
SG11201705964YA (en) 2017-08-30
EP4470611A2 (en) 2024-12-04
CA2974203A1 (en) 2016-07-28
BR112017015613A2 (en) 2018-03-13
TW201639556A (zh) 2016-11-16
US10117843B2 (en) 2018-11-06
US20190142777A1 (en) 2019-05-16
KR20170103967A (ko) 2017-09-13
JP2018503686A (ja) 2018-02-08
PH12017501304A1 (en) 2018-02-05
EP3247330A1 (en) 2017-11-29
JP2024129122A (ja) 2024-09-26
CN116036064A (zh) 2023-05-02
JP2021073186A (ja) 2021-05-13
RU2017129375A3 (https=) 2019-08-05
US20160206584A1 (en) 2016-07-21
JP7232235B2 (ja) 2023-03-02
MX2017009325A (es) 2018-02-09
US20210046029A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
JP7232235B2 (ja) レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法
JP2025000924A (ja) レボドパ及びカルビドパ腸管ゲル、並びに使用方法
JP5607550B2 (ja) 非オピオイド鎮痛剤及びオピオイド鎮痛剤の組合せを含む胃保持性持続放出剤形
US20140005269A1 (en) Polymeric matrix of polymer-lipid nanoparticles as a pharmaceutical dosage form
CN103889455B (zh) 稳定化乙哌立松医药组成物及含有上述组成物的缓释制剂
CN114599346A (zh) 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
BRPI0409133B1 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
KR102437003B1 (ko) 레보도파 주입 용액
CN113616597A (zh) 一种美洛昔康的注射剂及其制备方法和用途
CN102579358B (zh) 一种药物缓释微丸及其制备方法
EP3338802B1 (en) Biphasic creatine nutraceutic composition
US8158149B2 (en) Threo-DOPS controlled release formulation
WO2014110248A1 (en) Controlled release formulations of lorazepam
EP2446879A2 (en) Pharmaceutical composition containing carboxylosartan and a production method therefor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20171201